A Northwestern Medicine study has uncovered new insights that may aid in understanding and potentially treating one of the most common and aggressive forms of non-Hodgkin lymphoma, according to ...
MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology East ...
The transcription factor NF-κB is a key regulator of cell fate, extensively involved in various physiological and pathological processes such as ...
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Findings offer hope for new treatments targeting inflammation-related conditions Two new studies from the lab of Steven E.
Vietnam Investment Review on MSN
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback